ePrints

Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope

Lookup NU author(s): Dr Ben Thompson

Downloads

• Published version [.pdf]

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Abstract

© The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.Pharmacological management has advanced considerably since the 2015 British Society for Rheumatology axial spondyloarthritis (axSpA) guideline to incorporate new classes of biologic DMARDs (bDMARDs, including biosimilars), targeted synthetic DMARDs (tsDMARDs) and treatment strategies such as drug tapering. The aim of this guideline is to provide an evidence-based update on pharmacological management of adults with axSpA (including AS and non-radiographic axSpA) using b/tsDMARDs. This guideline is aimed at health-care professionals in the UK who care directly for people with axSpA, including rheumatologists, rheumatology specialist nurses, allied health professionals, rheumatology specialty trainees and pharmacists; people living with axSpA; and other stakeholders, such as patient organizations and charities.

Publication metadata

Author(s): Zhao SS, Harrison SR, Chan A, Clarke N, Davis C, Eddison J, Gregory WJ, Jones GT, Marzo-Ortega H, Murphy DJ, Sandhu V, Sengupta R, Siebert S, Thompson B, Webb D, Yates M, Gaffney K

Publication type: Article

Publication status: Published

Journal: Rheumatology Advances in Practice

Year: 2023

Volume: 7

Issue: 2

Online publication date: 15/05/2023

Acceptance date: 22/03/2023

Date deposited: 04/07/2023

ISSN (electronic): 2514-1775

Publisher: Oxford University Press

URL: https://doi.org/10.1093/rap/rkad039

DOI: 10.1093/rap/rkad039

Altmetrics

Funding

Share